Journal of Peking University(Health Sciences) ›› 2018, Vol. 50 ›› Issue (6): 1117-1119. doi: 10.19723/j.issn.1671-167X.2018.06.032

• Article • Previous Articles     Next Articles

A case of gout secondary to primary myelofibrosis

Lan-lan JI,Yan-jie HAO,Zhuo-li ZHANG()   

  1. Department of Rheumatology and Immunology,Peking University First Hospital, Beijing 100034, China
  • Received:2018-07-09 Online:2018-12-18 Published:2018-12-18
  • Contact: Zhuo-li ZHANG E-mail:zhuoli.zhang@126.com

RICH HTML

  

Abstract:

A 52-year-old man was referred to our department with a 2-year history of polyarthritis. He was diagnosed as gout due to acute arthritis of bilateral feet dorsum 2 years ago,but he didn’t receive any standard treatment. 1 year ago,there were more and more joints evolved during the gout attack,and many subcutaneous nodules occurred. When he presented to our clinic 1 month ago,the urate acid level was as high as 715 μmol/L. Moreover,we could find bone erosion in the X rays of his hand and foot,as well as synovitis,double contour sign and tophus on the ultrasound examination. The diagnosis of gout was clearly and definitely. However,he had leukocytosis and thrombocytosis for 4 years in the past history,and the urate acid level was only 400 μmol/L at that time. He also had well-controlled hypertension. The family history was unremarkable. Furthermore,we found megalosplenia on his physical examination. The bone marrow examination showed myelofibrosis and JAK2 V617F gene was positive. He was diagnosed as primary myelofibrosis and treated with interferon-α,together with urate acid-lowing therapy (febuxostat 60 mg once daily). Following-up for 1 year,the dosage of febuxostat decreased to 40 mg once daily,and the patient didn’t have gout attack again,some of the tophus diminished,and the urate acid level ranged from 400 to 500 μmol/L. Gout is a common disease in clinical practice,usually combined with metabolic syndrome,chronic renal failure and specific drugs using (diuretic and calcineurin inhibitors). However,it is relatively rare to see gout associated with myeloproliferative diseases,including polycythemia vera,primary thrombocythemia,primary myelofibrosis and chronic myelocytic leukemia.In these diseases,the turnover of nucleic acids is greatly augmented,and an excess of purine metabolites,including uric acid,is released. In the natural course of gout,the appearance of tophus from the first onset of arthritis usually takes several years. This patient only had one traditional risk factor,but his urate acid level was remarkably high and he developed tophus in a short term. After treatment of primary myelofibrosis,the symptom of gout partially alleviated. Careful physical examination and medical history taking lead to the diagnosis of secondary gout,which should be reminded in the daily practice.

Key words: Secondary gout, Tophus, Primary myelofibrosis, Myeloproliferative diseases

CLC Number: 

  • R593

Figure 1

The X-ray of bilateral wrists,hands (A) and feet (B),the arrows show the bone erosion"

Figure 2

The double contour sign of left talus. We can see the double contour sign of talus in the transverse scan (arrow)"

Figure 3

Tophus of right foot,there was a mass with low-high mixed echo above the talonavicular joint,with clear bound line and spotted Doppler signal (arrow)"

[1] 中华医学会风湿病学分会. 2016中国痛风诊疗指南[J]. 中华内科杂志, 2016,55(11):892-899.
[2] Neogi T, Jansen TLTA, Dalbeth N , et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis, 2015,74(10):1789-1798.
doi: 10.1136/annrheumdis-2015-208237 pmid: 4602275
[3] Yü TF . Secondary gout associated with myeloproliferative diseases[J]. Arthritis Rheum, 1965,8(5):765-771.
doi: 10.1002/art.1780080439 pmid: 5216775
[4] Gutman AB . The past four decades of progress in the knowledge of gout, with an assessment of the present status[J]. Arthritis Rheum, 1973,16(4):431-445.
doi: 10.1002/(ISSN)1529-0131
[5] Takahashi H, Hattori A, Shibata A . Profile of blood coagulation and fibrinolysis in chronic myeloproliferative disorders[J]. Tohoku J Exp Med, 1982,138(1):71-80.
doi: 10.1620/tjem.138.71 pmid: 6959382
[6] Barbui T, Carobbio A, Cervantes F , et al. Thrombosis in primary myelofibrosis: incidence and risk factors[J]. Blood, 2010,115(4):778-782.
doi: 10.1182/blood-2009-08-238956 pmid: 19965680
[7] Liu TT, Chen JB, Chen WJ , et al. Idiopathic myelofibrosis associated with renal extramedullary hematopoiesis and nephrotic syndrome: case report[J]. Chang Gung Med J, 2000,23(3):169-174.
pmid: 15641221
[1] Jiayi TIAN, Yixue GUO, Xia ZHANG, Xiaolin SUN, Jing HE. Flow cytometry analysis of normal range of natural killer cells and their subsets in peripheral blood of healthy Chinese adults [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 839-844.
[2] Yushu YANG, Xuan QI, Meng DING, Wei WANG, Huifang GUO, Lixia GAO. Diagnostic values of anti-salivary gland protein-1 antibody combined with anti-parotid secretory protein antibody for Sjögren's syndrome [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 845-852.
[3] Hua ZHONG, Yuan LI, Liling XU, Mingxin BAI, Yin SU. Application of 18F-FDG PET/CT in rheumatic diseases [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 853-859.
[4] Zhihui WU, Mingzhi HU, Qiaoying ZHAO, Fengfeng LV, Jingying ZHANG, Wei ZHANG, Yongfu WANG, Xiaolin SUN, Hui WANG. Immunomodulatory mechanism of umbilical cord mesenchymal stem cells modified by miR-125b-5p in systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 860-867.
[5] Dongwu LIU, Jie CHEN, Mingli GAO, Jing YU. Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 928-931.
[6] Zhengfang LI,Cainan LUO,Lijun WU,Xue WU,Xinyan MENG,Xiaomei CHEN,Yamei SHI,Yan ZHONG. Application value of anti-carbamylated protein antibody in the diagnosis of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 729-734.
[7] 佳佳 乔,聪 田,晓波 黄,军 刘. [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 745-749.
[8] Huina HUANG,Jing ZHAO,Xiangge ZHAO,Ziran BAI,Xia LI,Guan WANG. Regulatory effect of lactate on peripheral blood CD4+ T cell subsets in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 519-525.
[9] Limin REN,Chuchu ZHAO,Yi ZHAO,Huiqiong ZHOU,Liyun ZHANG,Youlian WANG,Lingxun SHEN,Wenqiang FAN,Yang LI,Xiaomei LI,Jibo WANG,Yongjing CHENG,Jiajing PENG,Xiaozhen ZHAO,Miao SHAO,Ru Li. Low disease activity and remission status of systemic lupus erythematosus in a real-world study [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 273-278.
[10] Xiaofei TANG,Yonghong LI,Qiuling DING,Zhuo SUN,Yang ZHANG,Yumei WANG,Meiyi TIAN,Jian LIU. Incidence and risk factors of deep vein thrombosis in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 279-283.
[11] Zhanhong LAI,Jiachen LI,Zelin YUN,Yonggang ZHANG,Hao ZHANG,Xiaoyan XING,Miao SHAO,Yuebo JIN,Naidi WANG,Yimin LI,Yuhui LI,Zhanguo LI. A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 284-292.
[12] Yi-jun HAN,Chang-hong LI,Xiu-ying CHEN,Jin-xia ZHAO. Comparison of clinical and immunological characteristics between primary Sjögren's syndrome patients with positive and negative anti-SSB antibody [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1000-1006.
[13] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[14] Xue ZOU,Xiao-juan BAI,Li-qing ZHANG. Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1013-1021.
[15] Wen-gen LI,Xiao-dong GU,Rui-qiang WENG,Su-dong LIU,Chao CHEN. Expression and clinical significance of plasma exosomal miR-34-5p and miR-142-3p in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1022-1027.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!